Why is Bharat Immunolog falling/rising?

As of 05-Sep, Bharat Immunological & Biological Corporation Ltd's stock is currently priced at 22.49, reflecting an increase of 0.44 or 2.0%. The stock has shown a positive performance today, outperforming its sector by 2.07%. Additionally, it has experienced a notable rise in investor participation, with delivery volume increasing by 555.91% against the 5-day average. However, despite this short-term uptick, the company faces significant long-term challenges, including a weak fundamental strength due to a lack of declared results in the last six months, a substantial decline in net sales and operating profit over the past five years, and a high debt-to-EBITDA ratio. The negative results reported for September 2023, including an 87.03% decline in net sales and the highest debt-equity ratio at 83.16%, further contribute to the stock's risky profile.
In the broader market context, Bharat Immunological's short-term return of +5.59% over the past week significantly outpaces the Sensex's return of +1.13% during the same period. However, the stock has consistently underperformed against the benchmark over the longer term, with a year-to-date return of -5.46% compared to the Sensex's +3.29%. This underperformance, coupled with the company's ongoing financial difficulties and lack of recent results, suggests that while there may be short-term gains, the long-term outlook remains precarious.